公开(公告)号：US20140295426A1

公开(公告)日：2014-10-02

申请号：US14235185

申请日：2012-07-27

申请人： Steven M. Albelda ,  Daniel Schwed ,  Chandra Galla Rao ,  Mark Connelly ,  Brad Foulk

发明人： Steven M. Albelda ,  Daniel Schwed ,  Chandra Galla Rao ,  Mark Connelly ,  Brad Foulk

IPC分类号： G01N33/574 ,  C12Q1/68

CPC分类号： G01N33/574 ,  C12Q1/6841 ,  G01N1/40 ,  G01N1/4077 ,  G01N33/57488 ,  G01N2333/705

摘要： A method for diagnosing or differentially diagnosing a cancer characterized by the presence of cancer cells in the pleural fluid of a mammalian subject, the method comprising contacting a sample of pleural fluid of the subject with colloidal magnetic particles coupled to a ligand which binds to a determinant on a cancer cell, but does not bind above a baseline threshold to other cellular and non-cellular components in pleural fluid; subjecting the pleural fluid-magnetic particle mixture to a magnetic field to produce a cell fraction enriched in ligand coupled-magnetic particle-bound cancer cells, if present in the pleural fluid; and analyzing the enriched fraction for the number of cancer cells in the pleural fluid. In certain aspects, this method involves preparing the pleural fluids for the above-noted method steps by, e.g., dilution of unprocessed pleural fluid. In certain aspect, the pleural fluid is subjected to the diagnostic method within 24 hours of withdrawal from the subject. This method has advantages to present diagnostic procedures for identifying malignant pleural effusions. The tumor cells present in pleural fluid can be characterized with cellular and molecular markers to determine prognostic and predictive factors.

摘要翻译： 一种用于诊断或差异诊断癌症的方法，其特征在于哺乳动物受试者的胸膜液中存在癌细胞，所述方法包括使受试者的胸膜液样品与结合至决定簇的配体偶联的胶体磁性颗粒接触 但不能在胸膜液中的其他细胞和非细胞成分的基线阈值以上结合; 使胸膜液 - 磁性颗粒混合物进行磁场以产生富含配体偶联磁性颗粒结合的癌细胞（如果存在于胸膜液中）的细胞部分; 并分析胸膜液中癌细胞数量的富集部分。 在某些方面，该方法包括通过例如稀释未加工的胸膜液来制备上述方法步骤的胸膜液。 在某些方面，在从受试者撤出的24小时内对胸膜液进行诊断。 该方法具有鉴定恶性胸腔积液的诊断方法的优点。 存在于胸膜液中的肿瘤细胞可以用细胞和分子标记进行表征，以确定预后和预测因素。

公开(公告)号：US20070154960A1

公开(公告)日：2007-07-05

申请号：US11701763

申请日：2007-02-02

申请人： Mark Connelly ,  Gerald Doyle ,  Galla Rao ,  Leon Terstappen

发明人： Mark Connelly ,  Gerald Doyle ,  Galla Rao ,  Leon Terstappen

IPC分类号： G01N33/567

CPC分类号： G01N33/6893 ,  G01N33/5091 ,  G01N2800/32 ,  Y10T436/101666 ,  Y10T436/107497 ,  Y10T436/108331 ,  Y10T436/2525 ,  Y10T436/25375

摘要： Elevated number of Circulating Endothelial Cells (CEC) have been implicated in disease conditions associated with the formation or destruction of blood vessels such as acute coronary syndrome, thrombocytopenic purpura, sickle cell disease, sepsis, lupus, nephrotic syndromes, rejection of organ transplants, surgical trauma and cancer. This invention provides a method for assessing the levels of CEC which vary between different studies using a sensitive enrichment, imaging, and enumberation analysis. CD146 is one of the most specific endothelium-associated cell-surface antigens which can be used in image cytometry. CEC analysis provides an essential tool in prognostic/diagnostic evaluation in the clinic.

摘要翻译： 循环内皮细胞数量增加已涉及与血管形成或破坏相关的疾病状况，如急性冠状动脉综合征，血小板减少性紫癜，镰状细胞病，败血症，狼疮，肾病综合征，器官移植排斥，外科手术 创伤和癌症。 本发明提供了一种用于评估使用敏感浓缩，成像和启发分析的不同研究之间变化的CEC水平的方法。 CD146是可用于图像细胞计数的最特异的内皮相关细胞表面抗原之一。 CEC分析为诊所的预后/诊断评估提供了重要的工具。

公开(公告)号：USD860635S1

公开(公告)日：2019-09-24

申请号：US35001209

申请日：2016-05-31

申请人： Mark Connelly

设计人： Mark Connelly

公开(公告)号：US20130157347A1

公开(公告)日：2013-06-20

申请号：US13543661

申请日：2012-07-06

申请人： Eric Topol ,  Samir Damani ,  Mark Connelly ,  Galla Chandra Rao

发明人： Eric Topol ,  Samir Damani ,  Mark Connelly ,  Galla Chandra Rao

IPC分类号： C12Q1/04

CPC分类号： C12Q1/04 ,  G01N15/1475 ,  G01N33/5026 ,  G01N33/5064 ,  G01N2800/32 ,  G01N2800/52

摘要： Compositions, systems, and methods comprising circulating endothelial cells (CECs) are provided. The compositions described herein utilize isolated CECs, including compositions in a form that allows analysis of the CECs. The systems described herein utilize isolated CECs and an analytical tool or an output from an analytical tool. The methods described herein are related to the use of isolated CECs and analytical tools for providing information, to a health care provider or the CEC donor, that is relevant to the cardiovascular health of the CEC donor. Thus, the compositions, systems and methods described herein involve both a transformation (e.g., non-isolated CECs to isolated CECs, or isolated CECs to analyzed CECs) and a machine (e.g., isolation tools and analytical tools).

摘要翻译： 提供了包含循环内皮细胞（CEC）的组合物，系统和方法。 本文描述的组合物使用分离的CEC，包括允许分析CEC的形式的组合物。 本文描述的系统使用分离的CEC和分析工具或来自分析工具的输出。 本文描述的方法涉及使用分离的CEC和分析工具来向医疗保健提供者或CEC供体提供与CEC供体的心血管健康相关的信息。 因此，本文所述的组合物，系统和方法涉及转化（例如，分离的CEC与分离的CEC的分离的CEC或分离的CEC的分离的CEC）和机器（例如，隔离工具和分析工具）。

公开(公告)号：US20060263836A1

公开(公告)日：2006-11-23

申请号：US11360072

申请日：2006-02-23

申请人： Mark Connelly ,  Mark Kopnitsky

发明人： Mark Connelly ,  Mark Kopnitsky

IPC分类号： G01N33/555

CPC分类号： G01N33/54313 ,  Y10T436/10

摘要： A method and composition for the purpose of detecting and measuring analytes, such as antibodies, which are capable of binding with certain binding partners such as antigens. A homogenous assay is performed in the presence of free unbound antibodies. Such a homogeneous assay testing for specific antibodies is herein possible by defining of test subsets of microparticles having specific antigens thereon which are capable of binding with specific target antibodies. The microparticle suspension also includes at least two calibration subsets of microparticles having a binding partner thereon with at least two known levels of concentration which is capable of binding with human antibodies for the purpose of assay calibration. A verification subset of microparticles is included with another binding partner thereon at a known concentration, capable of binding with anti-human antibodies. This suspension is incubated with a human sample and then is incubated with a tagging component which is measurable for calibration and verification and finally for determining the concentration of target antibodies bound to the test subsets. A separate verification subset of microparticles is included for verifying the calibration and for yielding a correction factor therefore. A complete calibration calculation is performed for each sample being tested. Preferably, the attaching component of the tagging component is the same molecule as the first binding partner material positioned on the calibration subsets of microparticles.

摘要翻译： 用于检测和测量能够与某些结合配偶体如抗原结合的分析物（例如抗体）的方法和组合物。 在游离未结合的抗体存在下进行均一的测定。 通过在其上具有能够与特异性靶抗体结合的具有特异性抗原的微粒的测试子集来定义对特异性抗体的这种均一测定测试。 微粒悬浮液还包括具有至少两个已知浓度浓度的至少两个具有结合配偶体的微粒的校准子集，其能够与人抗体结合以进行测定校准。 微粒的验证子集与另一个结合配偶体以已知的浓度包含在其中，能够与抗人抗体结合。 将该悬浮液与人样品一起孵育，然后与标记组分一起孵育，标记组分可测量用于校准和验证，最后用于测定与测试子集结合的靶抗体的浓度。 包括微粒的单独验证子集，用于验证校准和因此产生校正因子。 对每个被测样品进行完整的校准计算。 优选地，标记组分的附着成分与位于微粒校准子集上的第一结合配对物质相同。